Biotechnology
Rejuvenation Technologies Gets New Backing for Telomere-Targeted mRNA Platform
Jetstream backed Rejuvenation Technologies’ targeted TERT mRNA platform. The programs remain preclinical, and funding is not clinical proof.
Science. Medicine. Technology. Living longer.
Jetstream backed Rejuvenation Technologies’ targeted TERT mRNA platform. The programs remain preclinical, and funding is not clinical proof.